SYGNIS signs non-exclusive distribution agreement with Cambridge Bioscience Ltd. for UK and Ireland

05-May-2015 - United Kingdom
SYGNIS AG announced a distribution agreement with Cambridge Bioscience for the commercialization of SYGNIS’ proprietary product portfolio in the UK and Ireland.
Under the terms of the agreement, Cambridge Bioscience will promote, market, sell and support TruePrime™ products for primer-free WGA as well as SunScript™ thermostable reverse transcriptase kits for the translation of RNA into DNA to researchers in molecular biology in the UK and Ireland.
Cambridge Bioscience is a UK based distributor of cutting-edge life science research products including a broad portfolio of innovative products and technologies for molecular biology applications such as NGS, epigenetics, gene regulation, cloning, DNA extraction and purification, amplification, quantification, delivery as well as high-end instrumentation.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances